{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T05:32:10Z","timestamp":1784179930617,"version":"3.55.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T00:00:00Z","timestamp":1776038400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.vaccine.2026.128591","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T03:22:10Z","timestamp":1776482530000},"page":"128591","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Estimating the cost-effectiveness of respiratory syncytial virus (RSV) vaccination program for older Australian adults"],"prefix":"10.1016","volume":"82","author":[{"given":"Kishor K.","family":"Paul","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophy T.F.","family":"Shih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James G.","family":"Wood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allen L.","family":"Nazareno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Jan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony T.","family":"Newall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.vaccine.2026.128591_bb0005","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.jhin.2018.03.034","article-title":"Respiratory syncytial virus burden among adults during flu season: an underestimated pathology","volume":"100","author":"Kestler","year":"2018","journal-title":"J Hosp Infect"},{"issue":"3","key":"10.1016\/j.vaccine.2026.128591_bb0010","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.diagmicrobio.2016.02.025","article-title":"Morbidity and mortality among patients with respiratory syncytial virus infection: a 2-year retrospective review","volume":"85","author":"Anderson","year":"2016","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2026.128591_bb0015","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.46010","article-title":"Hospitalization following outpatient diagnosis of respiratory syncytial virus in adults","volume":"7","author":"Landi","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128591_bb0020","doi-asserted-by":"crossref","DOI":"10.1111\/irv.13031","article-title":"Respiratory syncytial virus disease burden in adults aged 60years and older in high-income countries: a systematic literature review and meta-analysis","volume":"17","author":"Savic","year":"2023","journal-title":"Influenza Other Respir Viruses"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128591_bb0025","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1111\/irv.13003","article-title":"Modelled estimates of hospitalisations attributable to respiratory syncytial virus and influenza in Australia, 2009-2017","volume":"16","author":"Nazareno","year":"2022","journal-title":"Influenza Other Respir Viruses"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128591_bb0030","doi-asserted-by":"crossref","DOI":"10.1111\/irv.70092","article-title":"Estimated incidence of hospitalisations and deaths attributable to respiratory syncytial virus infections in adults in Australia between 2010 and 2019","volume":"19","author":"Wiid","year":"2025","journal-title":"Influenza Other Respir Viruses"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128591_bb0035","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens12101196","article-title":"The changing landscape of respiratory syncytial virus infections","volume":"12","author":"Bem","year":"2023","journal-title":"Pathogens"},{"key":"10.1016\/j.vaccine.2026.128591_bb0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.126651","article-title":"Estimating the cost-effectiveness of maternal respiratory syncytial virus (RSV) vaccination in Australia: a dynamic and economic modelling analysis","volume":"46","author":"Nazareno","year":"2025","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.128591_bb0045","author":"Department of Health Disability, and Ageing"},{"key":"10.1016\/j.vaccine.2026.128591_bb0050","author":"Therapeutic Goods Administration"},{"key":"10.1016\/j.vaccine.2026.128591_bb0055","author":"Therapeutic Goods Administration"},{"key":"10.1016\/j.vaccine.2026.128591_bb0060","author":"Department of health and aged care"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128591_bb0065","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines11101605","article-title":"Comparative cost-effectiveness analysis of respiratory syncytial virus vaccines for older adults in Hong Kong","volume":"11","author":"Wang","year":"2023","journal-title":"Vaccines"},{"issue":"24","key":"10.1016\/j.vaccine.2026.128591_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2024.126294","article-title":"Cost-effectiveness of vaccinating adults aged 60 years and older against respiratory syncytial virus","volume":"42","author":"Hutton","year":"2024","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2026.128591_bb0075","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/cid\/ciad658","article-title":"Cost-effectiveness of prefusion f protein-based vaccines against respiratory syncytial virus disease for older adults in the United States","volume":"78","author":"Moghadas","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128591_bb0080","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s12916-025-03970-x","article-title":"Influential drivers of the cost-effectiveness of respiratory syncytial virus vaccination in european older adults: a multi-country analysis","volume":"23","author":"Li","year":"2025","journal-title":"BMC Med"},{"issue":"29","key":"10.1016\/j.vaccine.2026.128591_bb0085","doi-asserted-by":"crossref","first-page":"E989","DOI":"10.1503\/cmaj.240452","article-title":"Respiratory syncytial virus vaccination strategies for older Canadian adults: a cost-utility analysis","volume":"196","author":"Tuite","year":"2024","journal-title":"Can Med Assoc J"},{"key":"10.1016\/j.vaccine.2026.128591_bb0090","author":"Australian Bureau of Statistics"},{"key":"10.1016\/j.vaccine.2026.128591_bb0095","author":"Australian Bureau of Statistics"},{"key":"10.1016\/j.vaccine.2026.128591_bb0100","author":"Australian Government Actuary"},{"key":"10.1016\/j.vaccine.2026.128591_bb0105","author":"R Core Team"},{"issue":"43","key":"10.1016\/j.vaccine.2026.128591_bb0110","doi-asserted-by":"crossref","DOI":"10.21105\/joss.01686","article-title":"Welcome to the tidyverse","volume":"4","author":"Wickham","year":"2019","journal-title":"J Open Source Softw"},{"issue":"4","key":"10.1016\/j.vaccine.2026.128591_bb0115","doi-asserted-by":"crossref","first-page":"2002688","DOI":"10.1183\/13993003.02688-2020","article-title":"Burden of respiratory syncytial virus infection in community-dwelling older adults in europe (RESCEU): an international prospective cohort study","volume":"57","author":"Korsten","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.vaccine.2026.128591_bb0120","author":"Australian Government Department of Health and Aged Care"},{"issue":"17","key":"10.1016\/j.vaccine.2026.128591_bb0125","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1056\/NEJMoa043951","article-title":"Respiratory syncytial virus infection in elderly and high-risk adults","volume":"352","author":"Falsey","year":"2005","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128591_bb0130","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/irv.12686","article-title":"Estimates for quality of life loss due to respiratory syncytial virus","volume":"14","author":"Hodgson","year":"2020","journal-title":"Influenza Other Respir Viruses"},{"key":"10.1016\/j.vaccine.2026.128591_bb0140","author":"Australian Institute of Health and Welfare","year":"2020","journal-title":"National Hospitals Data Collection*"},{"issue":"10","key":"10.1016\/j.vaccine.2026.128591_bb0145","doi-asserted-by":"crossref","first-page":"447","DOI":"10.5694\/mja2.50159","article-title":"Respiratory syncytial virus-associated hospitalisations in Australia, 2006-2015","volume":"210","author":"Saravanos","year":"2019","journal-title":"Med J Aust"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128591_bb0150","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2209604","article-title":"Respiratory syncytial virus prefusion f protein vaccine in older adults","volume":"388","author":"Papi","year":"2023","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.vaccine.2026.128591_bb0155","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1056\/NEJMoa2213836","article-title":"Efficacy and safety of a bivalent RSV prefusion f vaccine in older adults","volume":"388","author":"Walsh","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128591_bb0160","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1093\/cid\/ciae010","article-title":"Efficacy and safety of respiratory syncytial virus (RSV) prefusion f protein vaccine (RSVPreF3 OA) in older adults over 2 RSV seasons","volume":"78","author":"Ison","year":"2024","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128591_bb0165","doi-asserted-by":"crossref","first-page":"e680","DOI":"10.1093\/cid\/ciaf061","article-title":"Efficacy, immunogenicity, and safety of the bivalent respiratory syncytial virus (RSV) prefusion F vaccine in older adults over 2 RSV seasons","volume":"81","author":"Walsh","year":"2025","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2026.128591_bb0170","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S2213-2600(25)00048-7","volume":"13","author":"Ison","year":"2025","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.vaccine.2026.128591_bb0175","series-title":"Exploratory analysis of the first 2 years of adult vaccination data recorded on AIR","author":"Hull","year":"2019"},{"key":"10.1016\/j.vaccine.2026.128591_bb0180","author":"Australian Government Department of Health and Aged Care"},{"key":"10.1016\/j.vaccine.2026.128591_bb0185","author":"Australian Government Department of Health and Aged Care"},{"key":"10.1016\/j.vaccine.2026.128591_bb0190","author":"Independent Health and Aged Care Pricing Authority"},{"key":"10.1016\/j.vaccine.2026.128591_bb0195","author":"The Pharmaceutical Benefits Scheme"},{"key":"10.1016\/j.vaccine.2026.128591_bb0200","author":"The Pharmaceutical Benefits Scheme"},{"issue":"Supplement_1","key":"10.1016\/j.vaccine.2026.128591_bb0205","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1093\/infdis\/jiac069","article-title":"Economic burden and health-related quality of life of respiratory syncytial virus and influenza infection in european community-dwelling older adults","volume":"226","author":"Mao","year":"2022","journal-title":"J Infect Dis"},{"issue":"Suppl. 1","key":"10.1016\/j.vaccine.2026.128591_bb0210","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1093\/infdis\/jiac064","article-title":"Cost-effectiveness of respiratory syncytial virus disease prevention strategies: maternal vaccine versus seasonal or year-round monoclonal antibody program in norwegian children","volume":"226","author":"Li","year":"2022","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128591_bb0215","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1186\/s12955-016-0537-0","article-title":"Health-related quality of life measured using the EQ-5D\u20135L: south australian population norms","volume":"14","author":"McCaffrey","year":"2016","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.vaccine.2026.128591_bb0220","author":"Medicines Australia"},{"key":"10.1016\/j.vaccine.2026.128591_bb0225","series-title":"Valuing vaccines: Ensuring Australia\u2019s access to vaccines today and tomorrow","author":"Shawview Consulting","year":"2021"},{"key":"10.1016\/j.vaccine.2026.128591_bb0230","series-title":"Applied methods of cost-effectiveness analysis in healthcare","author":"Gray","year":"2010"},{"key":"10.1016\/j.vaccine.2026.128591_bb0235","author":"Chemist warehouse"},{"key":"10.1016\/j.vaccine.2026.128591_bb0240","author":"Chemist warehouse"},{"issue":"7","key":"10.1016\/j.vaccine.2026.128591_bb0245","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1016\/j.vaccine.2024.02.041","article-title":"Impact and cost-effectiveness analyses of vaccination for prevention of respiratory syncytial virus disease among older adults in Ontario: a Canadian immunization research network (CIRN) study","volume":"42","author":"Shoukat","year":"2024","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vaccine.2026.128591_bb0250","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14760584.2024.2436183","article-title":"Cost-effectiveness of bivalent respiratory syncytial virus prefusion f vaccine for prevention of respiratory syncytial virus among older adults in Germany","volume":"24","author":"Averin","year":"2025","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2026.128591_bb0255","author":"Australian Institute of Health and Welfare"},{"key":"10.1016\/j.vaccine.2026.128591_bib256","unstructured":"New South Wales Health. NSW Respiratory Surveillance Report - week ending 25 October 2025 [cited 12 November 2025]. Available from https:\/\/www.health.nsw.gov.au\/Infectious\/covid-19\/Documents\/respiratory-surveillance-20251025.pdf."},{"key":"10.1016\/j.vaccine.2026.128591_bib257","unstructured":"Independent Hospital Pricing Authority. National Hospital Cost Data Collection (NHCDC) Public Sector 2022\u201323 [cited 24 October 2025]. Available from https:\/\/www.ihacpa.gov.au\/resources\/national-hospital-cost-data-collection-nhcdc-public-sector-2022-23."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26003993?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26003993?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T20:52:08Z","timestamp":1782247928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26003993"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":52,"alternative-id":["S0264410X26003993"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128591","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Estimating the cost-effectiveness of respiratory syncytial virus (RSV) vaccination program for older Australian adults","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.128591","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128591"}}